Amgen Inc.’s drug Tavneos, used to treat a severe form of blood vessel inflammation, has been tied to serious liver injuries and eight deaths, the US Food and Drug Administration said.
The FDA in January asked Amgen to pull Tavneos from the market, citing liver toxicity issues that affected the drug’s overall ...
Zai Lab (ZLAB) stock jumps as the company announces a global clinical trial collaboration with Amgen (AMGN). Read more here.
Amgen’s rare disease drug Tavneos is under mounting regulatory scrutiny, with the FDA warning of serious liver injuries, ...
By Puyaan Singh March 31 (Reuters) - The U.S. Food and Drug Administration on Tuesday said it has identified cases of liver ...
Amgen drug under FDA review Tavneos is linked to 76 liver injury cases including eight deaths; FDA advises liver monitoring ...
In late March 2026, the FDA warned of severe liver injuries, including vanishing bile duct syndrome, linked to ...
The Irish arm of bio-pharmaceutical giant Amgen has invested $407m (€353.3m) on capital expenditure on its Dun Laoghaire ...
The FDA has ramped up the pressure on Amgen to withdraw Tavneos for a rare vasculitis condition from the market, with a ...
Zai Lab and Amgen will collaborate on a clinical trial to evaluate a Zai Lab lung cancer therapy. Under the agreement, Amgen will sponsor a global phase 1b study to evaluate the safety and efficacy of ...
Repatha is the Only PCSK9 Inhibitor to Significantly Reduce the Risk of First CV Events in High-Risk Primary Prevention VESALIUS-CV Subgroup Findings Reinforce Benefit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results